Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL + Placebo in 1.5ml
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Prevention of Atherosclerotic Cardiovascular Disease
Conditions
Primary Prevention of Atherosclerotic Cardiovascular Disease
Trial Timeline
Mar 9, 2023 → Apr 16, 2029
NCT ID
NCT05739383About Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL + Placebo in 1.5ml
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL + Placebo in 1.5ml is a phase 3 stage product being developed by Novartis for Primary Prevention of Atherosclerotic Cardiovascular Disease. The current trial status is active. This product is registered under clinical trial identifier NCT05739383. Target conditions include Primary Prevention of Atherosclerotic Cardiovascular Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05739383 | Phase 3 | Active |
Competing Products
20 competing products in Primary Prevention of Atherosclerotic Cardiovascular Disease